KB-1393

Envafolimab

Home » Antibody » Envafolimab

Background

Envafolimab, an anti-programmed death ligand 1 (PD-L1) antibody administered via subcutaneous injection, is currently under development for addressing diverse solid tumors and chronic hepatitis B in China. In the United States, its applications encompass soft tissue sarcomas and biliary tract cancer. Distinguished by its single-domain nature, envafolimab stands out for its heightened solubility and expedited tissue penetration compared to full monoclonal antibodies. This characteristic facilitates its subcutaneous administration route. Following the pivotal phase II trial results, SC envafolimab recently secured approval in China for treating adult patients grappling with previously-treated microsatellite instability-high (MSI-H) or deficient MisMatch Repair (dMMR) advanced solid tumors.

Specifications

Catalog Number:
KB-1393
Cell Line Name:
Envafolimab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
PDL1
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1. Li J, Deng Y, Zhang W, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. J Hematol Oncol. 2021. 2. Zhang F, Wei H, Wang X, et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov. 2017;3:17004.
Please enable JavaScript in your browser to complete this form.